Why the study?
Does colchicine improve postpericardiotomy syndrome in a patient following lung lobectomy?
Does colchicine improve postpericardiotomy syndrome in a patient following lung lobectomy?
Colchicine may be an effective treatment for refractory postpericardiotomy syndrome following non-cardiac thoracic surgery such as lung lobectomy.
Answers are grounded in this paper and cite their sources.
Colchicine plus NSAIDs may relieve refractory postpericardiotomy syndrome after lobectomy; this case leaves open need for controlled trials.
Postpericardiotomy syndrome (PPS) is a frequent complication of various cardiac procedures that involve entry into the pericardium, but rarely occurs after pulmonary surgery because the pericardium is usually preserved during this procedure. The standard treatment for PPS is the administration of non-steroidal anti-inflammatory drugs (NSAIDs). Recent studies have indicated however, that colchicine may be useful for the treatment and prevention of this syndrome. Here, we describe the successful use of colchicine to treat PPS in a lung cancer patient who developed this complication following a lung lobectomy. A 64-year-old woman with a stage IA lung tumor underwent a left upper lobectomy with a mediastinal lymph node dissection. Severe precordial pain occurred 10 days after surgery, and accumulations of pericardial and pleural fluid were revealed by chest X-ray, echocardiogram, and chest computed tomography. These symptoms were not alleviated by antibiotics, thoracic cavity drainage, or NSAIDs. However, the administration of colchicine (initial dose of 1.0 mg and maintenance dose of 0.5 mg daily for three months) in combination with NSAIDs resolved these symptoms immediately after the first dosage. In addition, the patient remains free of any recurrent pericarditis at six months after this episode.
No takes yet. Share an insight, caveat, or question.
Eguchi et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: